Nuwellis shares surge 11.48% premarket as Q3 sequential revenue jumps 29%, driven by U.S. console sales and new outpatient therapy product launches.

Nuwellis surged 11.48% in premarket trading following the release of its Q3 2025 results, which highlighted a 29% sequential revenue increase to $2.2 million and key operational milestones. The company announced the first Aquadex therapies delivered in hospital-based outpatient settings under a new CMS code, the U.S. launch of a 24-hour circuit and dual-lumen catheter, and accelerated pediatric development via an NIH-funded collaboration. Management emphasized disciplined execution, U.S. market focus, and innovation in precision fluid management. Despite a 6% year-over-year revenue decline and a 30% rise in operating expenses, the sequential growth, product launches, and strategic shifts—including a manufacturing transition and international wind-down—signaled renewed momentum. These developments aligned with the stock’s sharp premarket rally, reflecting investor optimism about the company’s U.S. growth strategy and technological advancements.